Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 11;62(7):3475-3502.
doi: 10.1021/acs.jmedchem.8b01961. Epub 2019 Mar 21.

Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials

Affiliations

Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials

Rozalia A Dodean et al. J Med Chem. .

Abstract

Malaria remains one of the deadliest diseases in the world today. Novel chemoprophylactic and chemotherapeutic antimalarials are needed to support the renewed eradication agenda. We have discovered a novel antimalarial acridone chemotype with dual-stage activity against both liver-stage and blood-stage malaria. Several lead compounds generated from structural optimization of a large library of novel acridones exhibit efficacy in the following systems: (1) picomolar inhibition of in vitro Plasmodium falciparum blood-stage growth against multidrug-resistant parasites; (2) curative efficacy after oral administration in an erythrocytic Plasmodium yoelii murine malaria model; (3) prevention of in vitro Plasmodium berghei sporozoite-induced development in human hepatocytes; and (4) protection of in vivo P. berghei sporozoite-induced infection in mice. This study offers the first account of liver-stage antimalarial activity in an acridone chemotype. Details of the design, chemistry, structure-activity relationships, safety, metabolic/pharmacokinetic studies, and mechanistic investigation are presented herein.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1.
Figure 1.
Transition from dual-function acridone to broad-spectrum acridone chemotype.
Figure 2.
Figure 2.
Structures of 1,4/2,4/3,4-dichloro-acridones 100–102.
Figure 3.
Figure 3.
Acridones efficacy in the in vivo liver stage model in C57BL/6 male Albino mice infected with 50000 luciferase-expressing P. berghei sporozoites.
Scheme 1.
Scheme 1.
Synthesis of acridones 7–15, 23, 24, and 29–32 with a substitution at the 2/3 position of ring-A and (dialkylamino)alkoxy/chloroalkoxy moiety at the 6 position of ring-Ba aReagents and conditions: (i) Cu powder, K2CO3, pentanol, reflux, 5 h; (ii) Eaton’s acid, 90 °C, 5-24 h; (iii) HI, phenol, reflux, 3 h; (iv) C1-(CH2)n-R1/R2. HC1, K2CO3, acetone, reflux, 5-12 h; (v) Tf2O, pyridine, CH2C12, 0 °C-rt, 5 h; (vi) Pd(dba)2, DPPF, KOtBu, toluene, 100 °C, 8-12 h; (vii) BBr3, CH2C12, −78 °C-rt, 12 h; (viii) Br-(CH2)3-C1, K2CO3, acetone, reflux, 24 h; (ix) tert-butylamine, NaI, DMSO, 145 °C, 2 h.
Scheme 2.
Scheme 2.
Synthesis of acridones 38–55, 62 and 63 with disubstitutions at the 1 and 3 positions of ring-A, and alkoxy/(dialkylamino)alkoxy/chloroalkoxy moiety at the 6 position of ring-Ba aReagents and conditions: (i) Pd(dba)2, DPPF, KOtBu, toluene, 100 °C, 8-12 h; (ii) Eaton’s acid, 90 °C, 5-24 h; (iii) HI, phenol, reflux, 3 h; (iv) Br-(CH2)n-C1, K2CO3, acetone, reflux, 24 h; (v) alkylamine, NaI, DMSO, 145 °C, 2 h; (vi) C1-(CH2)n-R3.HC1, K2CO3, acetone, reflux, 3-12 h; (vii) Br-(CH2)2-Br, KI, K2CO3, acetone, reflux, 24 h; (viii) dipropylamine, KI, K2CO3, acetone, reflux, 18 h; (ix) Tf2O, pyridine, CH2C12, 0 °C-rt, 5 h.
Scheme 3.
Scheme 3.
Synthesis of acridones 70–86, 92, 93, 98 and 99 with disubstitutions at the 1 and 2 or the 2 and 3 positions of ring-A and (diethylamino)ethoxy/ethyl-amino/chloroalkoxy at the 6 position of ring-Ba aReagents and conditions: (i) Pd(dba)2, DPPF, KOtBu, toluene, 100 °C, 8-12 h; (ii) Eaton’s acid, 90 °C, 5-24 h; (iii) HI, phenol, reflux, 3 h; (iv) Br-(CH2)n-C1, K2CO3, acetone, reflux, 24 h; (v) alkylamine, NaI, DMSO, 145 °C, 2 h; (vi) C1-(CH2)n-Ri, K2CO3, acetone, reflux, 10-24 h; (vii) C1-(CH2)2-N(Et)2.HC1, K2CO3, acetone, reflux, 10 h; (viii) Br(CH2)2-N(Et)2.HBr, TBAC, K2CO3, acetone, reflux, 4 h; (ix) NH2-(CH2)2-N(Et)2, 2-acetylcyclohexanone, Cs2CO3, CuI, DMF, 100 °C, 4 h; (x) Tf2O, pyridine, CH2C12, 0 °C-rt, 5 h; (xi) Pd(OAc)2, XPhos, Cs2CO3, toluene, 110 °C, 5-8 h.
Scheme 4.
Scheme 4.
Synthesis of acridones 109–113, 119, 120, 123 and 128 with mono/di-substitutions on ring-A and (dialkylamino)alkoxy moiety at the 7 position of ring-Ba aReagents and Conditions: (i) Br-(CH2)2-C1, K2CO3, acetone, reflux, 10 h; (ii) dipropyl amine, NaI, DMSO, 145 °C, 3 h; (iii) Tf2O, pyridine, CH2C12, 0 °C-rt, 5 h; (iv) Pd(OAc)2, XPhos, Cs2CO3, toluene, 110 °C, 5-8 h; (v) Eaton’s acid, 90 °C, 5-24 h; (vi) BBr3, CH2C12, −78 °C-rt, 12 h; (vii) C1-(CH2)2-N(Et)2.HC1, K2CO3, acetone, reflux, 10 h; (viii) C1-(CH2)2- N(Pr)2.HC1, K2CO3, acetone, reflux, 10 h; (ix) Cu powder, K2CO3, pentanol, reflux, 5 h.

Similar articles

  • Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
    Kancharla P, Dodean RA, Li Y, Pou S, Pybus B, Melendez V, Read L, Bane CE, Vesely B, Kreishman-Deitrick M, Black C, Li Q, Sciotti RJ, Olmeda R, Luong TL, Gaona H, Potter B, Sousa J, Marcsisin S, Caridha D, Xie L, Vuong C, Zeng Q, Zhang J, Zhang P, Lin H, Butler K, Roncal N, Gaynor-Ohnstad L, Leed SE, Nolan C, Ceja FG, Rasmussen SA, Tumwebaze PK, Rosenthal PJ, Mu J, Bayles BR, Cooper RA, Reynolds KA, Smilkstein MJ, Riscoe MK, Kelly JX. Kancharla P, et al. J Med Chem. 2020 Jun 11;63(11):6179-6202. doi: 10.1021/acs.jmedchem.0c00539. Epub 2020 May 26. J Med Chem. 2020. PMID: 32390431 Free PMC article.
  • Development of Next-Generation Antimalarial Acridones with Radical Cure Potential.
    Dodean RA, Li Y, Zhang X, Caridha D, Madejczyk MS, Jin X, Dennis WE, Chetree R, Kudyba K, McEnearney S, Lee PJ, Blount C, DeLuca J, Vuong C, Pannone K, Dinh HT, Mdaki K, Leed S, Martin ML, Pybus BS, Pou S, Winter RW, Liebman KM, Williams R, Kumar A, Chim-Ong A, Cui L, Orena S, Assimwe J, Tibagambirwa I, Byaruhanga O, Angutoko P, Legac J, Kreutzfeld O, Rosenthal PJ, Cooper RA, Nilsen A, Riscoe MK, Roth A, Kancharla P, Kelly JX. Dodean RA, et al. J Med Chem. 2025 Apr 24;68(8):8817-8840. doi: 10.1021/acs.jmedchem.5c00419. Epub 2025 Apr 3. J Med Chem. 2025. PMID: 40179277 Free PMC article.
  • Discovery of dual function acridones as a new antimalarial chemotype.
    Kelly JX, Smilkstein MJ, Brun R, Wittlin S, Cooper RA, Lane KD, Janowsky A, Johnson RA, Dodean RA, Winter R, Hinrichs DJ, Riscoe MK. Kelly JX, et al. Nature. 2009 May 14;459(7244):270-3. doi: 10.1038/nature07937. Epub 2009 Apr 8. Nature. 2009. PMID: 19357645 Free PMC article.
  • New approaches in antimalarial drug discovery and development: a review.
    Aguiar AC, Rocha EM, Souza NB, França TC, Krettli AU. Aguiar AC, et al. Mem Inst Oswaldo Cruz. 2012 Nov;107(7):831-45. doi: 10.1590/s0074-02762012000700001. Mem Inst Oswaldo Cruz. 2012. PMID: 23147137 Review.
  • Comprehensive review on various strategies for antimalarial drug discovery.
    Mishra M, Mishra VK, Kashaw V, Iyer AK, Kashaw SK. Mishra M, et al. Eur J Med Chem. 2017 Jan 5;125:1300-1320. doi: 10.1016/j.ejmech.2016.11.025. Epub 2016 Nov 12. Eur J Med Chem. 2017. PMID: 27886547 Review.

Cited by

References

    1. WHO. World malaria report. 2016.
    1. Antony HA; Parija SC Antimalarial drug resistance: an overview. Trop. Parasitol. 2016, 6, 30–41. - PMC - PubMed
    1. Sinha S; Medhi B; Sehgal R. Challenges of drug-resistant malaria. Parasite 2014, 21, 61. - PMC - PubMed
    1. Thu AM; Phyo AP; Landier J; Parker DM; Nosten FH. Combating multi-drug resistant Plasmodium falciparum malaria. FEBS J. 2017, 284, 2569–2578. - PMC - PubMed
    1. White NJ; Pukrittayakamee S; Hien TT; Faiz MA; Mokuolu OA; Dondorp AM. Malaria. Lancet 2014, 383, 723–735. - PubMed

Publication types